Skip to main content

Top performance and excellence

The strategic cornerstones for the current financial year

Our long-term, strategic positioning is focused on providing our clients with top performance that excites because of its excellence in an increasingly global and digitalized contract research environment.

As we enter the new financial year 2022-2023, we have defined the cornerstones that will be the focus of our business activities over the next 12 months. Their implementation will make a valuable contribution to achieving our strategic positioning.

While maintaining our flexibility, performance strength and reliability in our day-to-day business, we devote our attention to the following points:

Using synergy effects of the SGS Group as a growth factor

Through cooperation opportunities with other institutes of the SGS Group, we expect an extended service portfolio that our clients benefit from.

Accelerated continuation of our digitalization project

We want to accelerate and complete our digitalization project in the coming financial year.

Identify and realize growth potential

In some markets, a change in the legal situation has led to an increase in the need for clinical trial services. We would like to take advantage of the resulting potential.

Leadership in innovation and quality

We continue to focus on methodological and consulting competence combined with high quality standards.

proderm is now part of SGS proderm is now part of SGS